MedTrace Logo

Injury and Illness Surveillance At the FIFA World Cup Qatar 2022TM

NCT05629156 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 705

Last updated 2025-02-11

No results posted yet for this study

Summary

The project aims to provide an overview of injury and illnesses during the FIFA World Cup Qatar 2022. All teams are invited to participate and record details on time-loss injury and illness occurrence and training and match exposure during the tournament. In order to assess the severity of injuries (based on the length of time a player is unable to play for), all injuries are to be monitored until they are fully rehabilitated, even if this is after the end of the tournament. This information will be recorded by the team physicians and provided on daily report forms to the research team. Data will be encrypted before analysis and only anonymized data will be published. Descriptive statistics are used to provide an overview of the participant demographics and injury and illness occurrence. Injury incidence is calculated as number of injuries per 1000 hours of exposure, and injury burden is calculated as time-loss days per 1000 hours of exposure. Injury incidence and burden will be reported for training and match injuries separately. Illness incidence is calculated per 365 exposure days.

Conditions

  • Injuries
  • Illness Physical
  • Illness, Mental

Interventions

OTHER

No intervention implemented. Observational study only

Observational study only. Injuries and illnesses and exposure is registered using standardized paper forms.

Sponsors & Collaborators

  • Aspetar Orthopaedic and Sports Medicine Hospital

    collaborator UNKNOWN

  • Federation Internationale de Football Association

    lead OTHER

Eligibility

Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2022-11-09
Primary Completion
2022-12-19
Completion
2024-06-11

Countries

  • Qatar

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05629156 on ClinicalTrials.gov